CliffBio
small molecule

IYUZEH

LATANOPROST

Loss of exclusivityJuly 2031latest FDA-listed patent expiry
CompanyThea →See this company's full patent-cliff portfolio

Drug detail

Brand nameIYUZEH
Active ingredientLATANOPROST
Strength0.005%
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalDecember 2022
Marketing statusRX

Listed patents

PatentExpiresType
8637054July 2031product

More from Thea

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

IYUZEH patent cliff — loss of exclusivity July 2031 | CliffBio